Australis Capital
1095 West Pender Street, Suite 305, Vancouver, BC, V6E 2M6, Canada
Overview
Australis Capital synthesizes of strategic alignment, and capital investment execution to build shareholder value in the cannabis value chain. It is a publicly traded market for cannabis.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Financial Services
Investment portfolio
- Folium Biosciences
Led · Equity · Jan 2019
Folium Biosciences operates as a vertically integrated producer, manufacturer and distributor of hemp-derived phytocannabinoids and owns the largest phytocannabinoid extraction and purification facility in the United States. The company supplies 0.0% THC phytocannabinoid-rich hemp oil produced via a chromatographic purification process that selectively removes the psychoactive component. Folium is certified by the Colorado Department of Public Health and Environment to produce 0.0% THC products and offers a broad product set including CBD hemp oil, gel caps, water-soluble CBD, e-liquid, concentrates, pet products, salves, tinctures, face masks and white-label items. Management has signaled growth expectations following the 2018 Farm Bill and is planning a new pharmaceutical division and completion of a Canadian facility in 2019. The company reported a $3 million investment from Australis Capital as part of a private placement announced in January 2019.
Team
Terry Booth
Chief Executive Officer & Founder
LinkedIn